Receptor.AI is the first preclinical-stage company to develop a whole drug discovery platform around ultimate selectivity to cell- and tissue-specific protein isoforms, allele variants, inherited and cancer mutations. At Receptor.AI, we understand that precision and individualised medicine require a profound insight into the molecular distinctions between malfunctioning and normal proteins. In order to achieve the goal of ultra-selectivity to highly similar protein variants, we created a unique set of technologies with five levels of selectivity assessment for the candidate compounds. We are passionate about our approach and believe that it will transform drug development by making it more personalised and effective for patients than ever before.